Vaccine EB‐101

  • With the preventive model of the vaccine it was observed that immunized animals did not develop the disease throughout their lives.
  • The vaccine was tested on transgenic animals carrying the principal genetic mutations responsible for the disease in humans.
  • With the therapeutic model it was verified that in the animals showing signs of brain degeneration, administration of the vaccine spectacularly reduced the genuine pathogenic signs that characterize Alzheimer’s disease in the brain: the amyloid beta deposits, the neurofibrillary tangles and the neuroinflammatory reactions mediated by the glial cells.
  • With this type of vaccine, the lethal meningoencephalitic reactions that caused the failure of previous models of anti-Alzheimer’s vaccines are avoided.

EB‐101 is a bivalent vaccine, with prophylactic and therapeutic activity, achieved by means of an immunization process in transgenic animals carrying the mutant human genes responsible for Alzheimer’s disease, in which the immunogen is encapsulated in S1P-rich liposomes.

In its long career, of over 20 years fighting Alzheimer’s disease, the EuroEspes Biomedical Research Center and its biotechnology subsidiary, EuroEspes Biotechnology, under the leadership of Dr. Ramón Cacabelos, have taken a transcendental step forward with a new model of vaccine that forestalls the disease and efficiently reduces the brain lesions in those cases where Alzheimer’s has already made an appearance. The official documentation of EuroEspes’ new vaccine EB-101 was approved by the United States patent office at the close of 2011, and the technical data of this new vaccine have been made public in an extensive work published in the renowned International Journal of Alzheimer’s Disease.
This vaccine of a preventive and therapeutic nature and totally innovative, is characterized by the introduction of a new adjuvant-immunogen designed to generate antibodies against the neuritic plaques where the amyloid beta (Aβ) protein that damages the brains of Alzheimer’s patients gathers. The other distinctive characteristic of this vaccine is that it is encapsulated in sphingosine-1-phosphate (S1P)-rich liposomes that contribute to neuronal regeneration. These two innovative characteristics confer a dual nature on the vaccine; prophylactic (preventive, before symptoms appear) and therapeutic (in those cases where symptoms of the disease have already made an appearance).
The team of scientists who took part in the project, led by Dr. Ramón Cacabelos and coordinated by Dr. Carmen Vigo, associate researcher to EuroEspes Biotechnology in California, was formed by Dr. Iván Carrera, from the Basic Neurosciences Department; Dr. Lucía Fernández‐Novoa, from the Medical Genomics Department; and Dr. Valter Lombardi, from the Health Biotechnology Department.